GRTS - Gritstone bio, Inc.
IEX Last Trade
0.0327
-2.422 -7,407.645%
Share volume: 0
Last Updated: Mon 21 Oct 2024 08:09:01 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.46
-2.42
-98.67%
Fundamental analysis
9%
Profitability
0%
Dept financing
16%
Liquidity
66%
Performance
1%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-67.42%
6 Months
-71.66%
1 Year
-90.32%
2 Year
-93.45%
Key data
Stock price
$0.03
DAY RANGE
$0.04 - $0.55
52 WEEK RANGE
$0.19 - $3.17
52 WEEK CHANGE
-$90.37
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Andrew R. Allen
Region: US
Website: gritstonebio.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gritstonebio.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for common solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine
Recent news